NCT00190957已完成4 期
Atomoxetine Treatment of Adults With ADHD and Comorbid Alcohol Abuse: A Randomized, Placebo-Controlled Trial
适应症
相关药物
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 入组人数
- 140
- 试验地点
- 15
- 主要终点
- To test that atomoxetine is superior to placebo in reducing ADHD severity as measured by the Adult ADHD Investigator Symptom Rating Scale (AISRS) Total score and is superior to placebo in time to relapse of alcohol abuse at 12 weeks.
研究概览
简要总结
Atomoxetine Treatment of Adults with ADHD and Comorbid Alcohol Abuse
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •You must be at least 18 years old.
- •You must have a diagnosis of ADHD and a diagnosis of alcohol abuse or dependence.
- •You must have acceptable results on blood and urine tests and an electrocardiogram (ECG).
- •Your recent drinking history must meet specific requirements.
排除标准
- •You have taken atomoxetine in the past.
- •You have a psychiatric disorder, other than ADHD and alcohol abuse or dependence, for which you will need psychiatric medication.
- •You have cognitive impairment (such as memory loss), a brain injury, or a seizure disorder.
- •You have a history of severe allergies to more than 1 class of medication or multiple bad reaction to drugs.
结局指标
主要结局
To test that atomoxetine is superior to placebo in reducing ADHD severity as measured by the Adult ADHD Investigator Symptom Rating Scale (AISRS) Total score and is superior to placebo in time to relapse of alcohol abuse at 12 weeks.
次要结局
- Total alcohol consumption (mean drinks/day) during the final week of treatment is lower in patients treated with atomoxetine than in patients receiving placebo.
- The proportion of drinking days is smaller for atomoxetine-treated patients compared with those in the placebo group.
- Time to relapse of alcohol abuse is longer for atomoxetine-treated patients compared with those in the placebo group.
- Number of drinks per drinking day is smaller for patients treated with atomoxetine compared with placebo.
- The proportion of substance use days, for substances other than alcohol, is smaller among patients treated with atomoxetine as compared with placebo.
- After approximately 12 weeks of treatment, patients who receive atomoxetine will have superior social and occupational functioning compared with those who receive placebo as assessed by changes in the EWPS.
- Global functioning as assessed by the CGI-Overall-S and the CGI-I are superior in patients treated with atomoxetine as compared with those treated with placebo.
- Improvement in depressive symptoms as assessed by the HAM-D-17.
- Improvement in anxiety symptoms as assessed by the HAM-A.
- Improvement in self-reported ADHD symptoms as assessed by the ASRS.
- Improvement in self-rated symptoms of alcohol cravings as assessed by the OCDS.
- Improvement in specific symptoms of ADHD as assessed by the WRAADDS.
- Improvement in the self-rated adaptive functioning as assessed by the ASR.
- Improvement in the informant-related adaptive functioning as assessed by the ABCL.
- Improvement in work, social, and home life functioning as assessed by the Sheehan Disability Scale.
- Improvement in general quality of life as assessed by the SF-36 Health Status Survey and the Q-LES-Q-SF.
研究者
研究点 (15)
Loading locations...
相似试验
已完成
不适用
Atomoxetine/Attention Deficit/ Hyperactive Disorder (ADHD)/Substance Use Disorder (SUD)in a Residential Treatment FacilityAttention Deficit Hyperactivity DisorderNCT00953862NYU Langone Health18
已完成
2 期
Atomoxetine for Treating Cocaine Abuse in Adults With Attention Deficit Hyperactivity Disorder (ADHD)Attention Deficit Disorder With HyperactivityCocaine-Related DisordersNCT00218543New York State Psychiatric Institute20
已完成
4 期
Effectiveness of ATMX in Treating Adolescents With ADHD and SUDAttention Deficit Disorder With HyperactivitySubstance-Related DisordersNCT00218322Massachusetts General Hospital108
已完成
2 期
Atomoxetine to Treat Adolescents With Coexisting Alcohol and Other Substance Use Disorder and ADHDSubstance Use DisordersAttention Deficit Hyperactivity DisorderNCT00029614University of Pittsburgh24
已完成
3 期
Study of Broader Efficacy of Atomoxetine in the Treatment of ADHD in Children/AdolescentsAttention Deficit Hyperactivity DisorderNCT00191659Eli Lilly and Company200